Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Oct 11;10(10):CD010315.
doi: 10.1002/14651858.CD010315.pub2.

Blood pressure targets for the treatment of people with hypertension and cardiovascular disease

Luis Carlos Saiz  1 , Javier Gorricho, Javier Garjón, Mª Concepción Celaya, Lourdes Muruzábal, Mª Del Mar Malón, Rodolfo Montoya, Antonio López
Affiliations
Meta-Analysis

Blood pressure targets for the treatment of people with hypertension and cardiovascular disease

Luis Carlos Saiz et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Hypertension is a prominent preventable cause of premature morbidity and mortality. People with hypertension and established cardiovascular disease are at particularly high risk, so reducing blood pressure below standard targets may be beneficial. This strategy could reduce cardiovascular mortality and morbidity but could also increase adverse events. The optimal blood pressure target in people with hypertension and established cardiovascular disease remains unknown.

Objectives: To determine if 'lower' blood pressure targets (≤ 135/85 mmHg) are associated with reduction in mortality and morbidity as compared with 'standard' blood pressure targets (≤ 140 to 160/ 90 to 100 mmHg) in the treatment of people with hypertension and a history of cardiovascular disease (myocardial infarction, angina, stroke, peripheral vascular occlusive disease).

Search methods: The Cochrane Hypertension Information Specialist searched the following databases for randomized controlled trials up to February 2017: the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1946), Embase (from 1974), the World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov. We also searched the Latin American and Caribbean Health Science Literature Database (from 1982) and contacted authors of relevant papers regarding further published and unpublished work. There were no language restrictions.

Selection criteria: We included randomized controlled trials (RCTs) with more than 50 participants per group and at least six months follow-up. Trial reports needed to present data for at least one primary outcome (total mortality, serious adverse events, total cardiovascular events, cardiovascular mortality). Eligible interventions were lower target for systolic/diastolic blood pressure (≤ 135/85 mmHg) compared with standard target for blood pressure (≤ 140 to 160/90 to 100 mmHg).Participants were adults with documented hypertension or who were receiving treatment for hypertension and cardiovascular history for myocardial infarction, stroke, chronic peripheral vascular occlusive disease or angina pectoris.

Data collection and analysis: Two review authors independently assessed search results and extracted data using standard methodological procedures expected by The Cochrane Collaboration.

Main results: We included six RCTs that involved a total of 9795 participants. Mean follow-up was 3.7 years (range 1.0 to 4.7 years). Five RCTs provided individual patient data for 6775 participants.We found no change in total mortality (RR 1.05, 95% CI 0.90 to 1.22) or cardiovascular mortality (RR 0.96, 95% CI 0.77 to 1.21; moderate-quality evidence). Similarly, no differences were found in serious adverse events (RR 1.02, 95% CI 0.95 to 1.11; low-quality evidence). There was a reduction in fatal and non fatal cardiovascular events (including myocardial infarction, stroke, sudden death, hospitalization or death from congestive heart failure) with the lower target (RR 0.87, 95% CI 0.78 to 0.98; ARR 1.6% over 3.7 years; low-quality evidence). There were more participant withdrawals due to adverse effects in the lower target arm (RR 8.16, 95% CI 2.06 to 32.28; very low-quality evidence). Blood pressures were lower in the lower' target group by 9.5/4.9 mmHg. More drugs were needed in the lower target group but blood pressure targets were achieved more frequently in the standard target group.

Authors' conclusions: No evidence of a difference in total mortality and serious adverse events was found between treating to a lower or to a standard blood pressure target in people with hypertension and cardiovascular disease. This suggests no net health benefit from a lower systolic blood pressure target despite the small absolute reduction in total cardiovascular serious adverse events. There was very limited evidence on adverse events, which lead to high uncertainty. At present there is insufficient evidence to justify lower blood pressure targets (≤ 135/85 mmHg) in people with hypertension and established cardiovascular disease. More trials are needed to answer this question.

PubMed Disclaimer

Conflict of interest statement

LC Saiz: None known.

J Gorricho: None known.

J Garjón: None known.

MC Celaya: None known.

L Muruzábal: None known.

R Montoya: None known.

A López: None known.

MM Malón: None known.

Figures

Figure 1
Figure 1
Results of the search.
Figure 2
Figure 2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figure 3
Figure 3
Forest plot of comparison: 1 Lower versus Standard, outcome: 1.1 Total mortality.
Figure 4
Figure 4
Forest plot of comparison: 1 Lower versus Standard, outcome: 1.2 Serious adverse events.
Figure 5
Figure 5
Forest plot of comparison: 1 Lower versus Standard, outcome: 1.4 Cardiovascular events.
Figure 6
Figure 6
Forest plot of comparison: 1 Lower versus Standard, outcome: 1.3 Cardiovascular mortality.
Analysis 1.1
Analysis 1.1
Comparison 1 Lower versus standard blood pressure targets for people with hypertension and history of cardiovascular disease, Outcome 1 Total mortality.
Analysis 1.2
Analysis 1.2
Comparison 1 Lower versus standard blood pressure targets for people with hypertension and history of cardiovascular disease, Outcome 2 Serious adverse events.
Analysis 1.3
Analysis 1.3
Comparison 1 Lower versus standard blood pressure targets for people with hypertension and history of cardiovascular disease, Outcome 3 Cardiovascular events.
Analysis 1.4
Analysis 1.4
Comparison 1 Lower versus standard blood pressure targets for people with hypertension and history of cardiovascular disease, Outcome 4 Cardiovascular mortality.
Analysis 1.5
Analysis 1.5
Comparison 1 Lower versus standard blood pressure targets for people with hypertension and history of cardiovascular disease, Outcome 5 Withdrawals due to adverse effects.
Analysis 1.6
Analysis 1.6
Comparison 1 Lower versus standard blood pressure targets for people with hypertension and history of cardiovascular disease, Outcome 6 Blood pressure target achieved at 1 year.
Analysis 1.7
Analysis 1.7
Comparison 1 Lower versus standard blood pressure targets for people with hypertension and history of cardiovascular disease, Outcome 7 Systolic blood pressure change from baseline at end of 1 year.
Analysis 1.8
Analysis 1.8
Comparison 1 Lower versus standard blood pressure targets for people with hypertension and history of cardiovascular disease, Outcome 8 Diastolic blood pressure change from baseline at end of 1 year.
Analysis 1.9
Analysis 1.9
Comparison 1 Lower versus standard blood pressure targets for people with hypertension and history of cardiovascular disease, Outcome 9 Number of antihypertensive drugs needed at the end of study.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

    1. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial—correction. JAMA2006; Vol. 295, issue 23:2726. [DOI: 10.1001/jama.295.23.2726-c] - DOI - PubMed
    2. Appel LJ, Middleton J, Miller ER 3rd, Lipkowitz M, Norris K, Agodoa LY, et al. The rationale and design of the AASK cohort study. Journal of the American Society of Nephrology : JASN 2003;14(7 Suppl 2):S166‐72. [PUBMED: 12819323] - PubMed
    3. Gassman JJ, Greene T, Wright JT Jr, Agodoa L, Bakris G, Beck GJ, et al. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). Journal of the American Society of Nephrology : JASN 2003;14(7 Suppl 2):S154‐65. [PUBMED: 12819322] - PMC - PubMed
    4. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases 2006;48(5):739‐51. [PUBMED: 17059993] - PubMed
    5. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288(19):2421‐31. [PUBMED: 12435255] - PubMed
    1. ACCORD Study Group. Cushman C, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood‐pressure control in type 2 diabetes mellitus. New England Journal of Medicine 2010;362(17):1575‐85. - PMC - PubMed
    2. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. American Journal of Cardiology 2007;99(12A):21i‐33i. [PUBMED: 17599422] - PubMed
    3. Cushman WC, Grimm RH Jr, Cutler JA, Evans GW, Capes S, Corson MA, et al. ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. American Journal of Cardiology 2007;99(12A):44i‐55i. [PUBMED: 17599425] - PubMed
    1. Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) Study ‐ patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Pressure 1994;3(5):322‐7. [PUBMED: 7866597] - PubMed
    2. Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) Study: 24‐month data on blood pressure and tolerability. Blood Pressure 1997;6(5):313‐7. [PUBMED: 9360003] - PubMed
    3. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood‐pressure lowering and low‐dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351(9118):1755‐62. [PUBMED: 9635947] - PubMed
    4. Hansson L, for the HOT Study Group. The Hypertension Optimal Treatment Study (the HOT Study). Blood Pressure 1993;2(1):62‐8. [PUBMED: 8193735] - PubMed
    5. Zanchetti A, Hansson L, Clement D, Elmfeldt D, Julius S, Rosenthal T, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J‐shaped curve exist in smokers?. Journal of Hypertension 2003;21(4):797‐804. [DOI: 10.1097/01.hjh.0000052482.18130.b2; PUBMED: 12658027] - DOI - PubMed
    6. Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. Journal of Hypertension 2001;19(6):1149‐59. [PUBMED: 11403365] - PubMed
    1. Fletcher K, Mant J, McManus R, Campbell S, Betts J, Taylor C, et al. Protocol for Past BP: a randomised controlled trial of different blood pressure targets for people with a history of stroke of transient ischaemic attack (TIA) in primary care. BMC Cardiovascular Disorders 2010;10:37. [DOI: 10.1186/1471-2261-10-37; PUBMED: 20696047] - DOI - PMC - PubMed
    2. Mant J, McManus R, Roalfe A, Fletcher K, Taylor C, Martin U, et al. RCT of different systolic blood pressure targets for people with a history or stroke or transient ischaemic attack: the PAST‐BP (Prevention After Stroke ‐ Blood Pressure) study. Journal of Human Hypertension 2014;28:627‐8.
    3. Mant J, McManus RJ, Roalfe A, Fletcher K, Taylor CJ, Martin U, et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST‐BP (Prevention After Stroke—Blood Pressure) randomised controlled trial. BMJ 2016;352:i708. [DOI: 10.1136/bmj.i708] - DOI - PMC - PubMed
    1. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clinical Trials (London, England) 2014;11(5):532‐46. [DOI: 10.1177/1740774514537404; PUBMED: 24902920] - DOI - PMC - PubMed
    2. SPRINT Research Group. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood‐pressure control. New England Journal of Medicine 2015;373(22):2103‐16. [DOI: 10.1056/NEJMoa1511939] - DOI - PMC - PubMed
    3. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow G, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016;315(24):2673‐82. [DOI: 10.1001/jama.2016.7050; PUBMED: 27195814] - DOI - PMC - PubMed

References to studies excluded from this review

    1. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood‐pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. New England Journal of Medicine 1994;330(13):877‐84. [PUBMED: 8114857] - PubMed
    1. NCT01230216. Effect of intensive blood pressure control on progression of coronary atherosclerosis: randomized evaluation by intravascular ultrasound. clinicaltrials.gov/ct2/show/NCT01230216 (first received 28 October 2010).
    1. Blackburn DJ, Krishnan K, Fox L, Ballard C, Burns A, Ford GA, et al. Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. Trials 2013;14:401. [PUBMED: 24266960] - PMC - PubMed
    1. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene‐Iordache B, Turturro M, et al. Blood‐pressure control for renoprotection in patients with non‐diabetic chronic renal disease (REIN‐2): multicentre, randomised controlled trial. Lancet 2005;365(9463):939‐46. [PUBMED: 15766995] - PubMed
    1. Arima H, Wang J, Bladin C, Heeley E, Billot L, Barzi F, et al. Rationale of the REstart or STop Antithrombotics Randomised Trial in Asia Pacific (RESTART‐AP). Cerebrovascular Diseases 2013;36(Suppl 1):39‐40.

References to studies awaiting assessment

    1. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non‐insulin‐dependent diabetes and hypertension. New England Journal of Medicine 1998;338(10):645‐52. [PUBMED: 9486993] - PubMed
    2. Estacio RO, Savage S, Nagel NJ, Schrier RW. Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes trial. Controlled Clinical Trials 1996;17(3):242‐57. [PUBMED: 8877260] - PubMed
    3. Savage S, Johnson Nagel N, Estacio RO, Feig PU, MacCarthy EP, Lukken NJ, et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online Journal of Current Clinical Trials 1993;104(‐):‐. [PUBMED: 8305994] - PubMed
    1. Hannson L. The BBB Study: the effect of intensified antihypertensive treatment on the level of blood pressure, side‐effects, morbidity and mortality in "well‐treated" hypertensive patients. Behandla Blodtryck Battre. Blood Pressure 1994;3(4):248‐54. [PUBMED: 7994450] - PubMed
    2. The BBB study group. The BBB study: a prospective randomized study of intensified antihypertensive treatment.. Journal of Hypertension 1988;6(9):693‐7. [PUBMED: 2903191] - PubMed
    1. Cardio‐Sis Study Group. Verdecchia P, Staessen JA, Achilli A, Simone G, Ganau A, Mureddu G, et al. Randomized study of traditional versus aggressive systolic blood pressure control (Cardio‐Sis): rationale, design and characteristics of the study population. Journal of Human Hypertension 2008;22(4):243‐51. [DOI: 10.1038/sj.jhh.1002313] - DOI - PubMed
    2. Reboldi G, Angeli F, Simone G, Staessen JA, Verdecchia P. Cardio‐Sis Investigators. Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease. Hypertension 2014;63(3):475‐82. [DOI: 10.1161/HYPERTENSIONAHA.113.02089] - DOI - PubMed
    3. Verdecchia P, Staessen JA, Angeli F, Simone G, Achilli A, Ganau G, et al. Cardio‐Sis investigators. Usual versus tight control of systolic blood pressure in non‐diabetic patients with hypertension (Cardio‐Sis): an open‐label randomised trial. Lancet 2009;374(9689):525‐33. [DOI: 10.1016/S0140-6736(09)61340-4] - DOI - PubMed

References to ongoing studies

    1. Zanchetti A, Liu L, Mancia G, Parati G, Grassi G, Stramba‐Badiale M, et al. Blood pressure and LDL‐cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension‐Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. Journal of Hypertension 2014;32(9):1888‐97. [DOI: 10.1097/HJH.0000000000000254; PUBMED: 24979303] - DOI - PubMed
    1. Kawano Y. HOSP study. Nihon Rinsho. Japanese Journal of Clinical Medicine 2006;64(Suppl 6):465‐9. [PUBMED: 16983778] - PubMed
    2. Kawano Y, Mannami T, Saitoh D, et al. Hypertension control based on home systolic pressure (HOSP) study: Design and interim report of the main study. Journal of Hypertension 2006;20(Suppl 6):329.
    1. White WB, Marfatia R, Schmidt J, Wakefield DB, Kaplan RF, Bohannon RW, et al. INtensive versus standard ambulatory blood pressure lowering to prevent functional DeclINe in the ElderlY (INFINITY). American Heart Journal 2013;165(3):258‐65.e1. [DOI: 10.1016/j.ahj.2012.11.008; PUBMED: 23453090] - DOI - PMC - PubMed
    1. ISRCTN37694103. How intensively should we treat blood PRESsure in established cERebral small VEssel disease?. www.isrctn.com/ISRCTN37694103 (first received 25 January 2012).
    1. NCT01198496. Recurrent stroke prevention clinical outcome study (RESPECTS) [Phase IV study for effect of intensive blood‐pressure control using anti‐hypertensive agents in essential hypertension with history of stroke]. clinicaltrials.gov/ct2/show/NCT01198496 (first received 28 August 2010).

Additional references

    1. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, et al. American Heart Association Council for High Blood Pressure Research, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Council on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115(21):2761‐88. [DOI: 10.1161/circulationaha.107.183885] - DOI - PubMed
    1. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD004349.pub2] - DOI - PubMed
    1. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD008277.pub2] - DOI - PMC - PubMed
    1. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, et al. J‐curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. European Heart Journal 2010;31(23):2897‐908. [DOI: 10.1093/eurheartj/ehq328] - DOI - PubMed
    1. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random‐effects meta‐analyses of randomized trials. Circulation 2011;123(24):2799‐810. [PUBMED: 21632497] - PubMed

References to other published versions of this review

    1. Gorricho J, Garjón J, Celaya MC, Muruzábal L, Montoya R, López Andrés A, et al. Blood pressure targets for the treatment of patients with hypertension and cardiovascular disease. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD010315] - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources